Business Wire
23 Jun 2026, 09:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Organon Canada and Henlius have launched BILDYOS and TUZEMTY biosimilars to the drugs PROLIA and XGEVA. — The introduction of biosimilars typically erodes market share and pricing power for the original brand-name drug manufacturers.
-0.40Which stocks this story touches
Organon is expanding its product portfolio and market access with the launch of two biosimilars.
Henlius is expanding access to its biosimilar treatments through a new partnership.
Amgen faces increased competition as biosimilars to its Prolia and Xgeva products are launched.
Continue reading
6 related stories
Top 1 mover · tap to explore
[mutual] Organon and Henlius are partners expanding access to denosumab biosimilars.
[mutual] Organon is launching biosimilars to compete with Amgen's PROLIA and XGEVA.
[mutual] Henlius is launching biosimilars to compete with Amgen's PROLIA and XGEVA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Globe News Wire
6h ago
